Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16717657 | 1.00 | MAPT (0.33) | MAPTATMENPP2LMNACYP2C9 | |
| SCHEMBL3645212 | 1.00 | MAPT (0.33) | MAPTATMENPP2LMNACYP2C9 | |
| SCHEMBL16716948 | 1.00 | MAPT (0.33) | MAPTATMENPP2LMNACYP2C9 | |
| SCHEMBL16717660 | 1.00 | MAPT (0.33) | MAPTATMENPP2LMNACYP2C9 | |
| SCHEMBL19617642 | 1.00 | MAPT (0.33) | MAPTATMENPP2LMNACYP2C9 | |
| SCHEMBL23275047 | 1.00 | MAPT (0.33) | MAPTATMENPP2LMNACYP2C9 | |
| SCHEMBL20422022 | 1.00 | MAPT (0.33) | MAPTATMENPP2LMNACYP2C9 | |
| SCHEMBL19765483 | 0.83 | ATM (0.41) | MAPTATMENPP2LMNACYP2C9 | |
| SCHEMBL19765490 | 0.83 | ATM (0.41) | MAPTATMENPP2LMNACYP2C9 | |
| SCHEMBL25153145 | 0.83 | ATM (0.41) | MAPTATMENPP2LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030872-B2 | N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-11999726-B2 | 5-methyl-4-fluoro-thiazol-2-yl compounds | ELI LILLY AND COMPANY | 2024-06-04 | — | — | US | disclosed |
| CN-113423711-B | Thieno [3,2-B ] pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use thereof | 建新公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2024026338-A1 | N-HETEROCYLIC GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-11839654-B2 | Combination therapy | ELI LILLY AND COMPANY (US) | 2023-12-12 | — | — | US | disclosed |
| EP-4284795-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| WO-2023070064-A1 | O-GLCNACASE (OGA) INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20180215751-A1 | 5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2018-08-02 | — | — | US | disclosed |
| WO-2018140299-A1 | N-[4-FLUORO-5-[[(2S,4S)-2-METHYL-4-[(5-METHYL-1,2,4-OXADIAZOL-3-YL)METHOXY]-1-PIPERIDYL]METHYL]THIAZOL-2-YL]ACETAMIDE AS OGA INHIBITOR | ELI LILLY AND COMPANY (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2017106556-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-06-22 | — | — | US | disclosed |
| EP-3071203-A2 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | Forma Therapeutics, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-20160257692-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9388161-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150232445-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| WO-2015074064-A2 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BAIR KENNETH W (US) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | MAPT 3708/4885ATM 2014/4885ENPP2 1329/4885 |
| US-20180215751-A1 | 5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUNDS | PSEN1, PSEN2, MAPT | MAPT 3/4885ATM 2823/4885ENPP2 2664/4885 |
| US-12030872-B2 | N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, CLK2, BRSK2 | MAPT 536/4885ATM 288/4885ENPP2 3949/4885 |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | MAPT 2499/4885ATM 2352/4885ENPP2 1139/4885 |
| US-20150232445-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | MAPT 3708/4885ATM 2014/4885ENPP2 1329/4885 |
| US-11655217-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | MAPT 2487/4885ATM 2601/4885ENPP2 1311/4885 |
| US-11839654-B2 | Combination therapy | MAPT, OGA, OAT | MAPT 1/4885ATM 976/4885ENPP2 1135/4885 |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | MAPT 2232/4885ATM 317/4885ENPP2 2930/4885 |
| US-20160257692-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | MAPT 3708/4885ATM 2014/4885ENPP2 1329/4885 |
| US-11999726-B2 | 5-methyl-4-fluoro-thiazol-2-yl compounds | MAPT, PSEN2, PSEN1 | MAPT 1/4885ATM 2476/4885ENPP2 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.